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Department of Internal Medicine
Figure 1: (above left) MRI of head 
21.6mm suprasellar mass which appears to be centered on the pituitary stalk neural hypophysis
Mass effect upon the hypothalamus and optic chiasm
Figure 2 (above right): MR-Angiography of Chest/Abdomen
Multiple findings consistent with Takayasu Arteritis
Diffuse mural thickening of the aortic arch + descending thoracic aorta—thickness (6mm)
Moderate stenoses of the proximal portions of the left subclavian artery and common carotids
Histiocytoses are group of disorders affecting myeloid progenitor cells
 The etiopathogenesis of histiocytoses are largely unknown, but BRAF-V600E mutation is frequently
implicated in the pathogenesis of these conditions
Histiocytoses are grouped into L-C-M-R-H classification presenting with various symptomology,
cytology, and prognosis dependent on category
 The L-group includes Langerhan, Non-Langerhan, and Mixed histiocytosis
 Langerhan Cell Histiocytosis (LCH) incidence is one case per million adults
Non-Langerhan Cell Histiocytosis (N-LCH) have only 500 documented cases and Mixed
Histiocytosis only around 100 cases (2+ others)
Histiocytoses clinical manifestations vary depending on organ involvement
 LCH has been known to affect long bones, skin, lymph nodes, spleen, and CNS
N-LCH can affect long bones, maxillary sinuses, large blood vessels, heart, CNS, skin and pituitary
gland (2)
Diagnosis is made with tissue biopsy with cytology, clinical manifestations, and imaging showing
multisystem involvement
Cytology testing include CD1a, CD68, CD163, CD207, S100, BRAFV600E,
 LCH and N-LCH carry a poor prognosis, which worsens with CV and CNS involvement
 Treatment for LCH, N-LCH, and Mixed Histiocytosis vary so differentiation is important
 LCH treatment is centered off radiation, resection, and targeted chemotherapy
N-LCH has no standardized treatment but trials show benefit with adding PEG-a unlike LCH
In August, A 42-year-old white female with a past medical history of migraines, depression, and 
fibromyalgia initially presented to Henry Ford Macomb Hospital after a syncopal event. The event 
occurred after having sutures removed one week status-post tenosynovitis release surgery and was 
transported to the ER immediately for evaluation. 
Upon arrival, the patient was feeling light-headed with associated headaches, visual changes, 
diaphoresis and fatigue which she had not experienced in the past. The patient denied symptoms of 
fever, shortness of breath, nausea, vomiting, focal weakness, or loss of sensation. The patient family 
history and social history were both unremarkable. Her past surgical history was significant for 
tenosynovitis release, cholecystectomy, sleeve gastroplasty, and umbilical hernial repair. The patient 
has no known drug allergies. The patient medications included cetirizine, cyclobenzaprine, duloxetine, 
lortab, ibuprofen, ativan, omeprazole, sertraline, tizanidine, and tramadol. Physical exam was notable 
for an anxious woman in mild distress, appearing pale, no obvious signs of trauma, normal heart and 
lung sounds, no abdominal tenderness, and no focal neurologic deficits. The patients vitals revealed a 
blood pressure of 71/47mmHg, HR 84bpm, 97.2 °F temporally, RR 16rpm, and SpO2 96% on room air.
Initially the event was presumed to be vasovagal in nature but a syncopal workup ensued with an EKG, 
CTA CT head and neck, and blood work. EKG was abnormal with a prolonged QT interval of 612 
which was not previously diagnosed. CTA with pulmonary embolism protocol incidentally found 
inflammation of the aorta and left subclavian vessel with mural thickening of descending aortic arc, 
CTA also showed stenosis of the celiac, superior mesenteric, and renal arteries. This finding was 
suspicious of Takayasu arteritis. CT head and neck revealed 14mm hypothalamic mass with optic 
chiasm involvement—however the patient denied visual impairment. The patient was discharged with 
plans to follow up with her rheumatologist and neurosurgery for evaluation of her hypothalamic mass. 
In December 2018, due to worsening of vision, A MRI imaging of the patients brain was obtained 
showing enlargement of the hypothalamic mass, measuring 21.3mm with associated intermittent 
horizontal diplopia occurring daily with continued fever, fatigue, and cold intolerance. Within a month, 
the patient had a right craniotomy preformed with partial tumor resection and was complicated by post-
operative cerebral edema and uncal herniation. Patient was given Decadron and intubated for a week to 
preserve the airway. The patient subsequently developed diabetes insipidus which was treated with 
desmopressin. Endocrinology diagnosed panhypopituitarism secondary to resection and hormone 
replacement therapy was initiated. The patient is still being treated for her condition.
Final pathology reports revealed BRAF positive Langerhans Cell Histiocytosis, staining positive for 
CD1a, S-100, Langerin, CD68 and CD168. Two weeks later, the patient was discharged home after 
stabilization.
Define Histiocytoses, L-CH, N-LCH, and Mixed Histiocytosis
 Explain the spectrum of L-type histiocytosis 
Discuss difference in organ system involvement
 Examine difficulty in diagnosis
Discuss importance of imaging, cytology, and clinical suspicion in diagnosis
Review classification schema and treatment
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As elucidated by this case, histiocytoses can be a difficult diagnosis and require adept clinical 
suspicion. Presentations vary greatly as a result of different organ involvement, from syncope from 
SIADH, to bone pain from lytic lesions. It is important to consider N-LCH, LCH, and Mixed 
histiocytosis in patients with osteolytic lesions and vascular or skin involvement. Histiocytoses can 
frequently inflict different organ systems thus clinical consideration should be given in patients with 
odd presentations that cannot be attributed to a particular cause especially when bone, skin, and 
vasculature are involved. In this case, the patients vascular involvement mimicked a vasculitis—
Takayasu arteritis—with aortitis, subclavian, and renal artery infliction but further evaluation 
illustrated a histiocytosis picture.
The different and hard to recognize presentations, such as this case makes classification of 
histiocytoses difficult as well. The subclassifications within the L-group of LCH, N-LCH, and Mixed 
histiocytosis are nebulous. Cases of these conditions are exceptionally rare which make the 
classification system difficult to effectively distinguish. The classification of these groups are 
primarily cytologic, but is this the best way to classify these conditions clinically? These processes 
pathogenesis are widely unknown, but are known be error in myeloid progenitors differentiation—
presumptively at different locations. This could provide context to why the tumors cell markers vary 
even amongst the same class. The biopsy for this case revealed CD-1a positive yet its CD-163/CD-68 
positivity technically classifies it “Non-Langerhan Cell”. Different lesions, such as this patients, 
doesn’t fit distinctly into any of the three as aforementioned categories which makes the current 
schema seem relatively ineffective. This patients clinical presentation with vascular involvement was 
more consistent with N-LCH; however, the cytology was inconclusive between LCH and N-LCH—
making it more consistent with mixed histiocytosis. Since cytology can be inconclusive especially in 
light of clinical findings, it makes the L-group of histiocytosis seem to be more of a spectrum of 
disease rather than distinct categories. 
LCH and N-LCH are important to differentiate as their management strategies differ in approach 
although there treatment guidelines are not well established. It is important to to recognize that these 
two disease processes can occur together manifesting as “mixed histiocytosis”. In patients with mixed 
histiocytosis with a BRAF V600E mutation Vemurafenib is recommended non-dependent on origin. If  
the patient can not tolerate Vemurafenib then the patient is treated with pegylated interferon alfa or 
MEK inhibitor. In patients without the BRAF mutation, conventional or pegylated interferon alfa is 
used and followed by then Cladribine and Cyclophosphamide in patients that cannot tolerate or fail 
interferon-a. Patients are often encouraged to enroll in clinical trials as there is not many set guidelines 
of treatment due to the rare nature of disease.
Histiocytoses present as a rare spectrum of disease with different presenting symptoms
Differences in diagnosis depends primarily on cytology and organ system involvement
 Treatment protocols vary for different histiocytosis although guidelines are not well established
 Patients that present under these rare condition should consider enrolling in clinical trials
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